Search research articles
Contact Us
Filters
Showing results (131-140 of 138) with videos related to
Page
of 14
Sort By:
You have reached the last page of results.
This site can display upto 138 results.
Blood
|
January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
Moritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Med (New York, N.Y.)
|
May 19, 2022
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection
Sophia Sobesky, Laman Mammadova, Melita Cirillo, et al.
Blood
|
January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 7, 2009
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
Martin L Sos, Stefanie Fischer, Roland Ullrich, et al.
Nature Communications
|
February 22, 2018
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D Herling, Nima Abedpour, Jonathan Weiss, et al.
Blood Cancer Journal
|
November 4, 2022
GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms
Xiangrong Geng, Chenguang Wang, Xin Gao, et al.
The Journal of Clinical Investigation
|
May 20, 2009
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
Martin L Sos, Kathrin Michel, Thomas Zander, et al.
Science Translational Medicine
|
December 17, 2010
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
Jonathan Weiss, Martin L Sos, Danila Seidel, et al.
Page
of 14
Search research articles
Search
Showing results (131-140 of 138) with videos related to
Sort By:
Page
of 14
You have reached the last page of results.
This site can display upto 138 results.
Blood
|
January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial
Moritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Med (New York, N.Y.)
|
May 19, 2022
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection
Sophia Sobesky, Laman Mammadova, Melita Cirillo, et al.
Blood
|
January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 7, 2009
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
Martin L Sos, Stefanie Fischer, Roland Ullrich, et al.
Nature Communications
|
February 22, 2018
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D Herling, Nima Abedpour, Jonathan Weiss, et al.
Blood Cancer Journal
|
November 4, 2022
GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms
Xiangrong Geng, Chenguang Wang, Xin Gao, et al.
The Journal of Clinical Investigation
|
May 20, 2009
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions
Martin L Sos, Kathrin Michel, Thomas Zander, et al.
Science Translational Medicine
|
December 17, 2010
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
Jonathan Weiss, Martin L Sos, Danila Seidel, et al.
Page
of 14